Exclusive negotiations with LISI Group to acquire its Medical division
FR
USA
Sycomore Corporate Finance acted as Financial Advisor to SK Capital
On July 9th, 2025, SK Capital, a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, entered into exclusive negotiations with LISI Group to acquire its Medical division.
Rationale
SK Capital’s investment will support Lisi Medical’s to accelerate the Company’s growth by expanding with existing and new customers and continuing to add new capabilities both organically and through M&A.
Lisi Medical is a leading MedTech CDMO focused on the production of high-precision metal components and assemblies serving global medical device original equipment manufacturers (“OEMs”). The Company’s products include instruments utilized in minimally invasive and robotic-assisted surgery as well as orthopedic implants. Lisi Medical operates four manufacturing sites with expertise in precision machining, forging, and engineering solutions, including highly automated production – two in Minnesota, U.S. and two in France.
SK Capital is a transformational private investment firm with a disciplined focus on the specialty materials, ingredients, and life sciences sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital currently has approximately $10 billion in assets under management as of December 31, 2024.